skip to main content

S. 1509: Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017

A bill to amend the Federal Food, Drug, and Cosmetic Act to authorize an extension of exclusivity periods for certain drugs that are approved for a new indication for a rare disease or condition, and for other purposes.

The bill’s titles are written by its sponsor.

Orrin Hatch

Sponsor. Senior Senator for Utah. Republican.

Read Text »
Last Updated: Jun 29, 2017
Length: 13 pages
Introduced:

Jun 29, 2017

Status:

Enacted Via Other Measures

Provisions of this bill were incorporated into other bills which were enacted, so there will not likely be further activity on this bill.

Provisions of this bill also appear in:

H.R. 2430: FDA Reauthorization Act of 2017
Enacted — Signed by the President on Aug 18, 2017. (compare text)
Prognosis:

20% chance of being enacted according to Skopos Labs (details)

History

Jun 29, 2017
 
Introduced

Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.

S. 1509 is a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“S. 1509 — 115th Congress: Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017.” www.GovTrack.us. 2017. November 23, 2017 <https://www.govtrack.us/congress/bills/115/s1509>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.